From 1 October 2026, individuals experiencing homelessness will be eligible for pneumococcal vaccination, marking a significant expansion of the UK's immunisation programme. This decision categorises people experiencing homelessness (PEH) as a new clinical risk group, acknowledging their increased vulnerability to serious infections.
Pneumococcal disease, caused by the Streptococcus pneumoniae bacterium, can lead to life-threatening conditions such as pneumonia, meningitis, and septicaemia. According to NHS guidelines, certain groups are already recommended to receive the pneumococcal vaccine due to higher risks of severe illness. These typically include infants, adults aged 65 and over, and individuals with long-term health conditions like chronic heart disease, chronic lung disease, and diabetes.
The inclusion of people experiencing homelessness reflects a growing understanding of the unique health challenges faced by this population. Factors such as poor nutrition, exposure to harsh weather, limited access to healthcare, and crowded living conditions in some temporary accommodations can significantly heighten their susceptibility to infectious diseases. Data from Public Health England (now UK Health Security Agency) has consistently highlighted the disproportionate health burden on homeless individuals, with significantly higher rates of respiratory illnesses compared to the general population.
The pneumococcal vaccine works by stimulating the body's immune system to produce antibodies against the bacteria, offering protection against serious infections. For adults, a single dose of the pneumococcal polysaccharide vaccine (PPV23) is usually sufficient for lifelong protection, although some high-risk individuals might require further doses. For children, a different vaccine, the pneumococcal conjugate vaccine (PCV), is part of the routine childhood immunisation schedule.
This proactive public health measure is expected to reduce hospital admissions and improve health outcomes for a particularly vulnerable segment of society. By broadening vaccine eligibility, the NHS aims to mitigate the impact of pneumococcal disease, which can be particularly severe and even fatal for those whose health is already compromised.